Analyst Ratings For ConvaTec Group PLC (LON:CTEC)
Today, JPMorgan Chase & Co. raised its price target on ConvaTec Group PLC (LON:CTEC) to GBX 305 per share.
There are 1 hold rating, 5 buy ratings on the stock.
The current consensus rating on ConvaTec Group PLC (LON:CTEC) is Buy (Score: 2.83) with a consensus target price of GBX 289.17 per share, a potential .
Some recent analyst ratings include
- 3/2/2017-Peel Hunt Reiterated Rating of Buy.
- 2/27/2017-Deutsche Bank AG Reiterated Rating of Buy.
- 1/19/2017-HSBC Holdings plc initiated coverage with a Buy rating.
- 12/6/2016-Goldman Sachs Group Inc Reiterated Rating of Buy.
About ConvaTec Group PLC (LON:CTEC)
ConvaTec Group Plc is a medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. It operates across market franchises, such as Advanced Wound Care, which provides advanced wound dressings and skin care products; Ostomy Care, which provides devices, accessories and services for people with a stoma, resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity and other causes; Continence and Critical Care, which provides products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida and other causes, and Infusion Devices, which provide disposable infusion sets. Its products include FlexiSeal Signal, FlexiSeal Fecal Collector and Intermittent Catheters.
Recent Trading Activity for ConvaTec Group PLC (LON:CTEC)
Shares of ConvaTec Group PLC closed the previous trading session at 260.55 up +4.85 1.90% with 3,185,472 shares trading hands.